Survival Analysis of Highly Frequent Mutations in PMP: Association with Progression-Free and Overall Survival

To investigate the correlation between highly frequent mutations and survival, we used the Kaplan-Meier method to estimate progression-free survival (PFS) and overall survival (OS). The analysis revealed that patients with MUC16 mutation had a significantly worse PFS (median, MUC16Mut vs MUC16WT, 8.0 vs 17.0 months; log-rank P = 0.016) and OS compared to those with wild-type (WT) (log-rank P = 0.004). Similarly, patients with TP53 or SMAD4 mutation also had a significantly poorer OS than those with WT, with patients with TP53 mutations reaching a median OS of 18 months. However, there was no statistically significant difference in PFS between patients carrying either of the two mutated genes and those with WT. Additionally, patients with TGFBR2 mutation had a median PFS of 10.0 months compared to 17.0 months in patients with TGFBR2 WT, and statistically significant differences were observed (log-rank P = 0.037), though no significant difference was observed in analysis of OS. On the other hand, GNAS, KRAS, TTN, SMAD2, and ATM mutation status were not significantly associated with survival and PFS.